Showing 1671-1680 of 2152 results for "".
- Aerie Pharmaceuticals Receives Marketing Authorization of Roclanda in Great Britainhttps://modernod.com/news/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclanda-in-great-britain/2479089/Aerie Pharmaceuticals announced that Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops solution (latanoprost + netarsudil) has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Roclanda is indicated for the reduction of el
- AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Markethttps://modernod.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/AffaMed Therapeutics and SIFI S.p.A. announced they have entered into an agreement to establish a joint venture to develop, manufacture and commercialize premium IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong. AffaMed will provide funding for growth
- Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion by 2026https://modernod.com/news/steady-growth-new-technologies-will-drive-retinal-surgery-device-market-to-1-36-billion-by-2026/2479005/The retinal surgical device market is expected to total more than $1.14 billion in 2021, with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report. Retina surgery device sales are driven almost entirely by vitrectomy, a procedure which involves removal of the
- SIFI Receives Marketing Authorization for Ophthalmic Products in in Turkeyhttps://modernod.com/news/sifi-recevies-marketing-authorizations-for-ophthalmic-products-in-in-turkey/2478996/SIFI, has announced that the Turkish Medicines and Medical Devices Agency (TMMDA) has approved the transfer of marketing authorizations from its former local distributor to its wholly owned subsidiary SIFI İlaç A.S. The approvals cover different formulations of ophthalmic drugs Netira, Netildex,
- Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/Ocugen and Bharat Biotech announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Under th
- Market Scope: Refractive Surgery to Grow 9.6% a Year Through 2025, Despite COVID-19https://modernod.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/Expanding use of products to treat refractive error will increase the role of devices and surgical procedures in the refractive landscape, according to a new Market Scope report. Globally, over 2.3 billion people require vision correction and have access to ophthalmic care. Global demand f
- Rayner Enters Canadian Ophthalmology Markethttps://modernod.com/news/rayner-enters-canadian-ophthalmology-market/2478773/Following the recent approval of incorporation, Rayner announced that is will now be offering the Rayner portfolio of IOLs and injectors directly to Canadian surgeons. The entry into the Canadian market will be led by Wade Allen, Director: Americas, Rayner Surgical Corp. The RayOne Aspheri
- EMA Receives Conditional Marketing Request for AstraZeneca’s COVID-19 Vaccinehttps://modernod.com/news/ema-receives-conditional-marketing-request-for-astrazenecas-covid-19-vaccine/2478752/The European Medicines Agency announced Tuesday that it received an application for conditional marketing authorization of AstraZeneca and the University of Oxford’s COVID-19 vaccine AZD1222. The regulator noted that the vaccine will be reviewed under an accelerated timeline with an opinion
- Ocugen and Bharat Biotech to Co-Develop COVID-19 Vaccine for the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-to-co-develop-covaxin-covid-19-vaccine-for-the-us-market/2478692/Ophthalmic biopharma company Ocugen has signed a letter of intent to co-develop Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, an advanced stage whole-viron inactivated vaccine candidate, for the United States market. Covaxin has been evaluated in approximately 1,000 subjects in pha
- Norlase Announces Newly Appointed Distributors into Major European Marketshttps://modernod.com/news/norlase-announces-newly-appointed-distributors-into-major-european-markets/2478640/Norlase has announced new distributor partnerships developed to advance market growth and global expansion of the Norlase family of green laser systems into France, Germany, Italy, Spain, and the United Kingdom. “We’re thrilled to announce that most ophthalmologists in Europe will no